Trial Profile
A Pilot Safety and Pharmacokinetic Study of MB-102 Versus Iohexol and the Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Oct 2023
Price :
$35
*
At a glance
- Drugs Relmapirazin (Primary) ; Iohexol
- Indications Acute kidney injury
- Focus Adverse reactions
- Sponsors MediBeacon
- 08 Sep 2021 Status changed from recruiting to completed.
- 23 Nov 2020 Protocol amended to add two dose arm (MB-102-- two doses) and planned number of patient changed, as reported by ClinicalTrial.gov record.
- 23 Nov 2020 Planned number of patients changed from 179 to 245.